Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
Xinling Wang, Shuai Xia, Qian Wang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3843-3843
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
Rory D. de Vries, Katharina S. Schmitz, Francesca T. Bovier, et al.
Science (2021) Vol. 371, Iss. 6536, pp. 1379-1382
Open Access | Times Cited: 194
Covid-19 pandemic and food: Present knowledge, risks, consumers fears and safety
Aleksandra Duda‐Chodak, Marcin Łukasiewicz, Gabriela Zięć, et al.
Trends in Food Science & Technology (2020) Vol. 105, pp. 145-160
Open Access | Times Cited: 94
Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease
Shao‐Chun Wang, Yeh Chen, Yuchuan Wang, et al.
American Journal of Cancer Research (2020) Vol. 10, Iss. 12, pp. 4538-4546
Closed Access | Times Cited: 69
Antiviral peptides against Coronaviridae family: A review
Hamid Heydari, Reza Golmohammadi, Reza Mirnejad, et al.
Peptides (2021) Vol. 139, pp. 170526-170526
Open Access | Times Cited: 59
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer
Carlo Cattrini, Melissa Bersanelli, Maria Maddalena Latocca, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2325-2325
Open Access | Times Cited: 67
Spike Glycoprotein-Mediated Entry of SARS Coronaviruses
Lin Wang, Ye Xiang
Viruses (2020) Vol. 12, Iss. 11, pp. 1289-1289
Open Access | Times Cited: 53
Design of Flavonoid‐Based Lipid Domains as Fusion Inhibitors to Efficiently Block Coronavirus and Other Enveloped Virus Infection
Nikesh Dewangan, Indrani Das Jana, Sandeep Yadav, et al.
Small (2025)
Closed Access
Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad‐spectrum neutralizing antibodies against SARS‐CoV‐2 and its variants
Ying Lu, An‐Qi Li, Fan Shen, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19
Shibi Muralidar, Gayathri Gopal, Senthil Visaga Ambi
Journal of Medical Virology (2021) Vol. 93, Iss. 9, pp. 5260-5276
Open Access | Times Cited: 39
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment
Zemene Demelash Kifle, Akeberegn Gorems Ayele, Engidaw Fentahun Enyew
Journal of Environmental and Public Health (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 33
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
Jie Zhou, Wei Xu, Zezhong Liu, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1652-1661
Open Access | Times Cited: 29
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
Pawan Kumar Raghav, Zoya Mann, Simran Kaur Ahluwalia, et al.
Journal of Pharmacological Sciences (2023) Vol. 152, Iss. 1, pp. 1-21
Open Access | Times Cited: 11
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al.
Genes & Diseases (2023) Vol. 10, Iss. 4, pp. 1402-1428
Open Access | Times Cited: 11
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
Danwei Yu, Yuanmei Zhu, Tao Jiao, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 1227-1240
Open Access | Times Cited: 23
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Xinling Wang, Lujia Sun, Zezhong Liu, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2
Hsiao‐Fan Chen, Wei‐Jan Wang, Chung‐Yu Chen, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 9
Structural understanding of SARS-CoV-2 virus entry to host cells
Kim Le, Shrute Kannappan, Truc Kim, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 9
Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
Rory D. de Vries, Katharina S. Schmitz, Francesca T. Bovier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 24
Can the Nasal Cavity Help Tackle COVID-19?
Bissera Pilicheva, Radka Boyuklieva
Pharmaceutics (2021) Vol. 13, Iss. 10, pp. 1612-1612
Open Access | Times Cited: 22
Silver nanoparticles against SARS-CoV-2 and its potential application in medical protective clothing – a review
Toufique Ahmed, R. Tuğrul Oğulata, Sabiha Sezgin Bozok
Journal of the Textile Institute (2021) Vol. 113, Iss. 12, pp. 2825-2838
Closed Access | Times Cited: 20
Electrochemical and Mechanistic Study of Oxidative Degradation of Favipiravir by Electrogenerated Superoxide through Proton-Coupled Electron Transfer
Tatsushi Nakayama, Ryo Honda
ACS Omega (2021) Vol. 6, Iss. 33, pp. 21730-21740
Open Access | Times Cited: 16
Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view
Ali Najmeddin, Mina Bahrololoumi Shapourabadi, Mahdi Behdani, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2021) Vol. 1865, Iss. 11, pp. 129974-129974
Open Access | Times Cited: 15
A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review
Priyanka Dash, Subhashree Mohapatra, Sayantan Ghosh, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 13
Peptide candidates for the development of therapeutics and vaccines against β-coronavirus infection
Rounak Chourasia, Srichandan Padhi, Loreni Chiring Phukon, et al.
Bioengineered (2022) Vol. 13, Iss. 4, pp. 9435-9454
Open Access | Times Cited: 9
Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry
Margot Morin‐Dewaele, S. Bartier, François Berry, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top